The Experts below are selected from a list of 1821 Experts worldwide ranked by ideXlab platform
Christian Raulin - One of the best experts on this subject based on the ideXlab platform.
-
treatment of Xanthelasma palpebrarum using a pulsed dye laser a prospective clinical trial in 38 cases
Dermatologic Surgery, 2010Co-Authors: Syrus Karsai, Agnieszka Czarnecka, Christian RaulinAbstract:BACKGROUND Several studies have reported positive results of nonablative laser treatment of Xanthelasma palpebrarum, but the published evidence is weak and inconclusive. OBJECTIVE To systematically evaluate the effect of pulsed dye laser (PDL) treatment of Xanthelasmas. MATERIALS AND METHODS Twenty female Caucasian patients with 38 lesions (≤1 mm above skin level) were enrolled. They received up to five treatment sessions with a PDL (wavelength, 585 nm; energy fluence, 7 J/cm2; pulse duration, 0.5 ms; spot size, 10 mm; number of passes, 2) at 2- to 3-week intervals. Photographs were taken before each treatment session and 4 weeks after the last treatment. Two independent examiners categorized clearance into four groups (no clearance [ 75%]). Patient satisfaction was assessed on a verbal rating scale. RESULTS Approximately two-thirds of the lesions showed clearance greater than 50%, and one-quarter had clearance greater than 75%. Interrater reliability was excellent (contingency coefficient >0.7 at all visits). Treatments were well tolerated and had no major side effects. Patient satisfaction was generally high. CONCLUSION PDL is a promising approach for treating Xanthelasmas, especially when multiple sessions are performed. The authors have indicated no significant interest with commercial supporters.
-
Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser
Lasers in surgery and medicine, 1999Co-Authors: Christian Raulin, Matthias P. Schoenermark, Saskia Werner, Baerbel GreveAbstract:Background and Objective Due to its delicate location near the eye and the high recurrence rate, the therapy of Xanthelasma palpebrarum is a difficult surgical task. Besides chemical, physical, and surgical procedures, various laser systems have been used to treat these lesions (argon laser, pulsed dye laser, and CO2 laser). This study was designed to critically evaluate the use of the ultrapulsed CO2 laser for the treatment of Xanthelasma palpebrarum. Study Design/Materials and Methods We report about the standardized treatment of 23 patients (52 periorbital Xanthelasmas) and the results obtained after one treatment with a new generation, ultrapulsed CO2 laser (COHERENT Ultrapulse 5000C, Palo Alto, CA; 250–500 mJ; 600–900 μsec; 10,600 nm). The follow-up time was 10 months. Results All lesions could be removed completely with a single laser treatment. As for side effects, only transient pigmental changes (4% hyperpigmentations, 13% hypopigmentations) and no visible scarring was observed. Three patients (13%) developed a recurrence of Xanthelasma. Conclusions The ultrapulsed CO2 laser is an effective and safe therapeutic alternative to the hitherto described approaches. Lasers Surg. Med. 24:122–127, 1999. © 1999 Wiley-Liss, Inc.
-
Treatment of Xanthelasma palpebrarum with the pulsed dye laser
Lasers in Surgery and Medicine, 1996Co-Authors: Matthias P Schonermark, Christian RaulinAbstract:Background and Objective Treatment of Xanthelasma palpebrarum may prove difficult due to its delicate location at the periorbita and its sometimes extensive dimension. During recent years, carbon dioxide and argon lasers have been used with good results. However, local anesthesia is always required, and there is a concrete risk of scarring and pigmentation changes after the treatment. Study Design/Patients and Methods: In this case report, we describe for the first time the treatment of Xanthelasmas with the pulsed dye laser. Results This technique can be carried out without anesthesia and shows excellent cosmetic results. Conclusion We see the pulsed dye laser as a good alternative to the hitherto used other two laser types in the treatment of Xanthelasma palpebrarum. © 1996 Wiley-Liss, Inc.
Ping Chen - One of the best experts on this subject based on the ideXlab platform.
-
Gastric Xanthelasma may be a warning sign of intestinal metaplasia: A cross‑sectional study.
Oncology reports, 2020Co-Authors: Dinghong Xiao, Xin Tong, Xiaoqin Yuan, Ping ChenAbstract:Certain conflicting conclusions have been drawn that gastric Xanthelasma is related to H. pylori, atrophic gastritis, intestinal metaplasia, and early gastric cancer. The aim of this study was to examine the relationship between gastric Xanthelasma and upper gastrointestinal (GI) endoscopic or pathological features. A cross‑sectional study was completed. A total of 8,634 patients who underwent stomach biopsy and who had no gastrectomy history were enrolled in the study. The patients were divided into two groups according to the presence or absence of gastric Xanthelasma. The relationship between gastric Xanthelasma and demographic characteristics (including age and sex), endoscopic features (including peptic ulcer, bile reflux, and gastric poly), or pathological features (including atrophy, intestinal metaplasia, H. pylori, dysplasia, and gastric cancer) was analyzed. Age/sex matched analysis was also performed to exclude the influence of age and sex. The results revealed that out of the 8,634 patients, 3.54% patients had Xanthelasma. Gastric Xanthelasma was significantly associated with age (55.76 vs. 49.17 years, P 0.05) of gastric Xanthelasma for intestinal metaplasia. In conclusion, gastric Xanthelasma may be an independent endoscopic warning sign of intestinal metaplasia.
-
gastric Xanthelasma may be a warning sign of intestinal metaplasia a cross sectional study
Oncology Reports, 2020Co-Authors: Dinghong Xiao, Xin Tong, Xiaoqin Yuan, Ping ChenAbstract:Certain conflicting conclusions have been drawn that gastric Xanthelasma is related to H. pylori, atrophic gastritis, intestinal metaplasia, and early gastric cancer. The aim of this study was to examine the relationship between gastric Xanthelasma and upper gastrointestinal (GI) endoscopic or pathological features. A cross‑sectional study was completed. A total of 8,634 patients who underwent stomach biopsy and who had no gastrectomy history were enrolled in the study. The patients were divided into two groups according to the presence or absence of gastric Xanthelasma. The relationship between gastric Xanthelasma and demographic characteristics (including age and sex), endoscopic features (including peptic ulcer, bile reflux, and gastric poly), or pathological features (including atrophy, intestinal metaplasia, H. pylori, dysplasia, and gastric cancer) was analyzed. Age/sex matched analysis was also performed to exclude the influence of age and sex. The results revealed that out of the 8,634 patients, 3.54% patients had Xanthelasma. Gastric Xanthelasma was significantly associated with age (55.76 vs. 49.17 years, P 0.05) of gastric Xanthelasma for intestinal metaplasia. In conclusion, gastric Xanthelasma may be an independent endoscopic warning sign of intestinal metaplasia.
Baerbel Greve - One of the best experts on this subject based on the ideXlab platform.
-
Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser
Lasers in surgery and medicine, 1999Co-Authors: Christian Raulin, Matthias P. Schoenermark, Saskia Werner, Baerbel GreveAbstract:Background and Objective Due to its delicate location near the eye and the high recurrence rate, the therapy of Xanthelasma palpebrarum is a difficult surgical task. Besides chemical, physical, and surgical procedures, various laser systems have been used to treat these lesions (argon laser, pulsed dye laser, and CO2 laser). This study was designed to critically evaluate the use of the ultrapulsed CO2 laser for the treatment of Xanthelasma palpebrarum. Study Design/Materials and Methods We report about the standardized treatment of 23 patients (52 periorbital Xanthelasmas) and the results obtained after one treatment with a new generation, ultrapulsed CO2 laser (COHERENT Ultrapulse 5000C, Palo Alto, CA; 250–500 mJ; 600–900 μsec; 10,600 nm). The follow-up time was 10 months. Results All lesions could be removed completely with a single laser treatment. As for side effects, only transient pigmental changes (4% hyperpigmentations, 13% hypopigmentations) and no visible scarring was observed. Three patients (13%) developed a recurrence of Xanthelasma. Conclusions The ultrapulsed CO2 laser is an effective and safe therapeutic alternative to the hitherto described approaches. Lasers Surg. Med. 24:122–127, 1999. © 1999 Wiley-Liss, Inc.
Yukio Osaki - One of the best experts on this subject based on the ideXlab platform.
-
gastric Xanthelasma may be a warning sign for the presence of early gastric cancer
Journal of Gastroenterology and Hepatology, 2014Co-Authors: Akira Sekikawa, Hirokazu Fukui, Takanori Maruo, Takehiko Tsumura, Takashi Kanesaka, Yoshihiro Okabe, Yukio OsakiAbstract:Background and Aim The significance of gastric Xanthelasma in relation to gastric disease still remains unclear. We investigated the prevalence and significance of gastric Xanthelasma in patients with atrophic gastritis and gastric cancer. Methods A total of 3238 patients who underwent endoscopic examinations of the upper gastrointestinal tract were enrolled. We retrospectively investigated the presence of gastric Xanthelasma, the severity of gastric atrophy, and the presence of gastric cancer, and examined the relationship between gastric Xanthelasma and various clinicopathological features. Results Gastric Xanthelasma was detected in 249 (7.7%) of the 3238 patients and was significantly associated with age ≥ 65 years, male gender, open-type atrophy, and the presence of gastric cancer (P < 0.0001, P = 0.0002, P < 0.0001 and P < 0.0001, respectively). Multivariate analysis revealed that the presence of gastric cancer was independently related to the presence of gastric Xanthelasma (odds ratio 6.19 [3.95–9.70], P < 0.0001). Age/sex/atrophy-matched control analysis demonstrated that the presence of gastric Xanthelasma was significantly associated with the presence of gastric cancer (P < 0.0001). Moreover, the presence of Xanthelasma in the upper region of the stomach was significantly associated with gastric cancer (P = 0.002). Gastric Xanthelasma was observed in 50 (47.6%) of 105 patients with gastric cancer. Conclusion Gastric Xanthelasma may serve as a warning sign for the presence of gastric cancer.
-
Gastric Xanthelasma may be a warning sign for the presence of early gastric cancer
Journal of gastroenterology and hepatology, 2014Co-Authors: Akira Sekikawa, Hirokazu Fukui, Takanori Maruo, Takehiko Tsumura, Takashi Kanesaka, Yoshihiro Okabe, Yukio OsakiAbstract:Background and Aim The significance of gastric Xanthelasma in relation to gastric disease still remains unclear. We investigated the prevalence and significance of gastric Xanthelasma in patients with atrophic gastritis and gastric cancer. Methods A total of 3238 patients who underwent endoscopic examinations of the upper gastrointestinal tract were enrolled. We retrospectively investigated the presence of gastric Xanthelasma, the severity of gastric atrophy, and the presence of gastric cancer, and examined the relationship between gastric Xanthelasma and various clinicopathological features. Results Gastric Xanthelasma was detected in 249 (7.7%) of the 3238 patients and was significantly associated with age ≥ 65 years, male gender, open-type atrophy, and the presence of gastric cancer (P
Dinghong Xiao - One of the best experts on this subject based on the ideXlab platform.
-
Gastric Xanthelasma may be a warning sign of intestinal metaplasia: A cross‑sectional study.
Oncology reports, 2020Co-Authors: Dinghong Xiao, Xin Tong, Xiaoqin Yuan, Ping ChenAbstract:Certain conflicting conclusions have been drawn that gastric Xanthelasma is related to H. pylori, atrophic gastritis, intestinal metaplasia, and early gastric cancer. The aim of this study was to examine the relationship between gastric Xanthelasma and upper gastrointestinal (GI) endoscopic or pathological features. A cross‑sectional study was completed. A total of 8,634 patients who underwent stomach biopsy and who had no gastrectomy history were enrolled in the study. The patients were divided into two groups according to the presence or absence of gastric Xanthelasma. The relationship between gastric Xanthelasma and demographic characteristics (including age and sex), endoscopic features (including peptic ulcer, bile reflux, and gastric poly), or pathological features (including atrophy, intestinal metaplasia, H. pylori, dysplasia, and gastric cancer) was analyzed. Age/sex matched analysis was also performed to exclude the influence of age and sex. The results revealed that out of the 8,634 patients, 3.54% patients had Xanthelasma. Gastric Xanthelasma was significantly associated with age (55.76 vs. 49.17 years, P 0.05) of gastric Xanthelasma for intestinal metaplasia. In conclusion, gastric Xanthelasma may be an independent endoscopic warning sign of intestinal metaplasia.
-
gastric Xanthelasma may be a warning sign of intestinal metaplasia a cross sectional study
Oncology Reports, 2020Co-Authors: Dinghong Xiao, Xin Tong, Xiaoqin Yuan, Ping ChenAbstract:Certain conflicting conclusions have been drawn that gastric Xanthelasma is related to H. pylori, atrophic gastritis, intestinal metaplasia, and early gastric cancer. The aim of this study was to examine the relationship between gastric Xanthelasma and upper gastrointestinal (GI) endoscopic or pathological features. A cross‑sectional study was completed. A total of 8,634 patients who underwent stomach biopsy and who had no gastrectomy history were enrolled in the study. The patients were divided into two groups according to the presence or absence of gastric Xanthelasma. The relationship between gastric Xanthelasma and demographic characteristics (including age and sex), endoscopic features (including peptic ulcer, bile reflux, and gastric poly), or pathological features (including atrophy, intestinal metaplasia, H. pylori, dysplasia, and gastric cancer) was analyzed. Age/sex matched analysis was also performed to exclude the influence of age and sex. The results revealed that out of the 8,634 patients, 3.54% patients had Xanthelasma. Gastric Xanthelasma was significantly associated with age (55.76 vs. 49.17 years, P 0.05) of gastric Xanthelasma for intestinal metaplasia. In conclusion, gastric Xanthelasma may be an independent endoscopic warning sign of intestinal metaplasia.